Nezameslami Rezvan, Nezameslami Alireza, Mehdikhani Bahareh, Mosavi-Jarrahi Alireza, Shahbazi Amirhossein, Rahmani Amirhossein, Masoudi Ali, Yeganegi Maryam, Akhondzardaini Razieh, Bahrami Mohammad, Aghili Kazem, Neamatzadeh Hossein
Department of Ophthalmology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Asian Pac J Cancer Prev. 2025 May 1;26(5):1641-1651. doi: 10.31557/APJCP.2025.26.5.1641.
To propose a framework for enhancing the reporting quality of genetic association studies by adapting the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
A systematic review was performed on case-control and cohort studies published in peer-reviewed journals up to October 7, 2024. Eligible studies reported on single nucleotide polymorphisms (SNPs) and gene expression profiles. Data collection consisted of a thorough examination of methodologies, population stratification, phenotype definitions, and ethical aspects concerning informed consent and data sharing.
The adaptation of the PRISMA guidelines created a cohesive reporting framework that improved reproducibility in 67% of 150 studies reviewed, up from 34% before the adaptation. Reported biases significantly decreased, with population stratification issues falling from 42% to 18% (p<0.01). Comprehensive reporting of genetic variants rose from 50% to 85% post-adaptation, aiding biological interpretation of results. A literature review found that only 60% of analyzed meta-analyses adhered to PRISMA standards, revealing notable deficiencies in sample characteristics, methodologies, and statistical reporting, including effect sizes and confidence intervals. Expert consultations indicated a need for clearer guidelines on population stratification, sample selection criteria, and gene-environment interactions. Recommendations for PRISMA adaptation include specific reporting items for genetic nuances, standardized methodologies, and attention to ethical considerations in genetic research. A proposed framework for ongoing evaluation and updates will emphasize interdisciplinary collaboration and transparency to enhance the reproducibility and credibility of genetic research findings.
The customized adaptation of PRISMA guidelines greatly improves the methodological quality and ethical standards of genetic association studies, enhancing the integrity and validity of research findings. These adaptations mark a critical advancement in the rigor and transparency of such research. By tackling the complexities of genetic data, researchers can enhance the comparability and reproducibility of their results, thereby furthering personalized medicine and public health.
通过调整系统评价与Meta分析的首选报告项目(PRISMA)指南,提出一个提高基因关联研究报告质量的框架。
对截至2024年10月7日在同行评审期刊上发表的病例对照研究和队列研究进行系统评价。符合条件的研究报告了单核苷酸多态性(SNP)和基因表达谱。数据收集包括对方法、人群分层、表型定义以及有关知情同意和数据共享的伦理方面进行全面审查。
PRISMA指南的调整创建了一个连贯的报告框架,在所审查的150项研究中,67%的研究提高了可重复性,高于调整前的34%。报告的偏倚显著减少,人群分层问题从42%降至18%(p<0.01)。基因变异的全面报告在调整后从50%升至85%,有助于对结果进行生物学解释。一项文献综述发现,只有60%的分析Meta分析符合PRISMA标准,在样本特征、方法和统计报告(包括效应大小和置信区间)方面存在明显不足。专家咨询表明,需要在人群分层、样本选择标准和基因-环境相互作用方面制定更明确的指南。对PRISMA调整的建议包括针对基因细微差别的特定报告项目、标准化方法以及关注基因研究中的伦理考量。一个用于持续评估和更新的提议框架将强调跨学科合作和透明度,以提高基因研究结果的可重复性和可信度。
PRISMA指南的定制调整极大地提高了基因关联研究的方法学质量和伦理标准,增强了研究结果的完整性和有效性。这些调整标志着此类研究在严谨性和透明度方面取得了关键进展。通过应对基因数据的复杂性,研究人员可以提高其结果的可比性和可重复性,从而推动个性化医疗和公共卫生的发展。